Deucravacitinib at EULAR 2022 Save
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on:
- Safety of Deucravacitinib https://bit.ly/3NtZQxe
- Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on:
- Safety of Deucravacitinib https://bit.ly/3NtZQxe
- Deucravacitinib in SLE https://bit.ly/3Mh5nG0
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.